{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T16:38:21Z","timestamp":1783528701339,"version":"3.55.0"},"reference-count":41,"publisher":"Frontiers Media SA","content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2018.00411","type":"journal-article","created":{"date-parts":[[2018,3,2]],"date-time":"2018-03-02T04:21:00Z","timestamp":1519964460000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":56,"title":["Autoantibodies May Predict Immune-Related Toxicity: Results from a Phase I Study of Intralesional Bacillus Calmette\u2013Gu\u00e9rin followed by Ipilimumab in Patients with Advanced Metastatic Melanoma"],"prefix":"10.3389","volume":"9","author":[{"given":"Jessica","family":"Da Gama Duarte","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sagun","family":"Parakh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miles C.","family":"Andrews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Woods","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anupama","family":"Pasam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Candani","family":"Tutuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Ostrouska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan M.","family":"Blackburn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Behren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Cebon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2018,3,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/nrclinonc.2017.43","article-title":"Targeted agents and immunotherapies: optimizing outcomes in melanoma","volume":"14","author":"Luke","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1200\/JCO.2014.56.2736","article-title":"Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma","volume":"33","author":"Schadendorf","year":"2015","journal-title":"J Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1200\/JCO.2005.01.128","article-title":"Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and montanide ISA 51 for patients with resected stages III and IV melanoma","volume":"23","author":"Sanderson","year":"2005","journal-title":"J Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"2010","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus dacarbazine for previously untreated metastatic melanoma","volume":"364","author":"Robert","year":"2011","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1002\/ssu.2980050608","article-title":"Active specific immunotherapy in malignant melanoma","volume":"5","author":"Morton","year":"1989","journal-title":"Semin Surg Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1111\/j.1445-2197.1978.tb05804.x","article-title":"Preliminary results of a randomized trial of adjuvant immunotherapy in patients with malignant melanoma who have lymph node metastases","volume":"48","author":"Morton","year":"1978","journal-title":"Aust N Z J Surg"},{"key":"B8","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/S0025-7125(16)31890-9","article-title":"BCG immunotherapy as a systemic adjunct to surgery in malignant melanoma","volume":"60","author":"Morton","year":"1976","journal-title":"Med Clin North Am"},{"key":"B9","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1097\/00000658-197410000-00029","article-title":"BCG immunotherapy of malignant melanoma: summary of a seven-year experience","volume":"180","author":"Morton","year":"1974","journal-title":"Ann Surg"},{"key":"B10","first-page":"225","article-title":"Treatment of malignant melanoma by intratumoral injection of BCG","volume":"39","author":"Pinsky","year":"1973","journal-title":"Natl Cancer Inst Monogr"},{"key":"B11","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/S0022-5347(17)46969-2","article-title":"The use of bacillus Calmette\u2013Gu\u00e9rin in the therapy of bladder carcinoma in situ","volume":"134","author":"Brosman","year":"1985","journal-title":"J Urol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1002\/1097-0142(19830401)51:7<1323::AID-CNCR2820510724>3.0.CO;2-2","article-title":"Effect of intravesical bacillus Calmette\u2013Gu\u00e9rin (BCG) on carcinoma in situ of the bladder","volume":"51","author":"Herr","year":"1983","journal-title":"Cancer"},{"key":"B13","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/S0022-5347(17)46976-X","article-title":"Intravesical bacillus Calmette\u2013Gu\u00e9rin therapy for superficial bladder cancer: effect of bacillus Calmette\u2013Gu\u00e9rin viability on treatment results","volume":"134","author":"Kelley","year":"1985","journal-title":"J Urol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1245\/ASO.2004.02.018","article-title":"Peripheral blood CD4+ T-cell response before postoperative active immunotherapy correlates with clinical outcome in metastatic melanoma","volume":"11","author":"Hsueh","year":"2004","journal-title":"Ann Surg Oncol"},{"key":"B15","first-page":"158","article-title":"Immunological factors which influence response to immunotherapy in malignant melanoma","volume":"68","author":"Morton","year":"1970","journal-title":"Surgery"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1002\/1097-0142(197905)43:5<1630::AID-CNCR2820430511>3.0.CO;2-Z","article-title":"Prospective comparison of intralesional and multipuncture BCG in recurrent intradermal melanoma","volume":"43","author":"Nathanson","year":"1979","journal-title":"Cancer"},{"key":"B17","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1056\/NEJM197310182891603","article-title":"Complications of BCG immunotherapy in patients with cancer","volume":"289","author":"Sparks","year":"1973","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1007\/BF02557273","article-title":"Active immunotherapy by reinduction with a polyvalent allogeneic cell vaccine correlates with improved survival in recurrent metastatic melanoma","volume":"9","author":"Hsueh","year":"2002","journal-title":"Ann Surg Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2913","DOI":"10.1200\/JCO.1998.16.9.2913","article-title":"Correlation of specific immune responses with survival in melanoma patients with distant metastases receiving polyvalent melanoma cell vaccine","volume":"16","author":"Hsueh","year":"1998","journal-title":"J Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1002\/ijc.11242","article-title":"Treatment of patients with progressive unresectable metastatic melanoma with a heterologous polyvalent melanoma whole cell vaccine","volume":"106","author":"Vilella","year":"2003","journal-title":"Int J Cancer"},{"key":"B21","doi-asserted-by":"publisher","first-page":"8508","DOI":"10.1200\/jco.2007.25.18_suppl.8508","article-title":"An international, randomized, phase III trial of bacillus Calmette\u2013Gu\u00e9rin (BCG) plus allogeneic melanoma vaccine (MCV) or placebo after complete resection of melanoma metastatic to regional or distant sites","volume":"25","author":"Morton","year":"2007","journal-title":"J Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1158\/1078-0432.CCR-14-1860","article-title":"Immune escape mechanisms as a guide for cancer immunotherapy","volume":"21","author":"Beatty","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B23","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1080\/14789450.2017.1347042","article-title":"Advances in the development of human protein microarrays","volume":"14","author":"Duarte","year":"2017","journal-title":"Expert Rev Proteomics"},{"key":"B24","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"B25","doi-asserted-by":"publisher","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","article-title":"Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria","volume":"15","author":"Wolchok","year":"2009","journal-title":"Clin Cancer Res"},{"key":"B26","doi-asserted-by":"publisher","first-page":"e0153725","DOI":"10.1371\/journal.pone.0153725","article-title":"Augmentation of autoantibodies by Helicobacter pylori in Parkinson\u2019s disease patients may be linked to greater severity","volume":"11","author":"Suwarnalata","year":"2016","journal-title":"PLoS One"},{"key":"B27","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/978-94-007-5811-7_3","article-title":"Protein function microarrays: design, use and bioinformatic analysis in cancer biomarker discovery and quantitation","volume-title":"Bioinformatics of Human Proteomics","author":"Duarte","year":"2013"},{"key":"B28","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1038\/nrc1669","article-title":"Cancer\/testis antigens, gametogenesis and cancer","volume":"5","author":"Simpson","year":"2005","journal-title":"Nat Rev Cancer"},{"key":"B29","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene laherparepvec improves durable response rate in patients with advanced melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J Clin Oncol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1109.e","DOI":"10.1016\/j.cell.2017.08.027","article-title":"Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy","volume":"170","author":"Ribas","year":"2017","journal-title":"Cell"},{"key":"B31","doi-asserted-by":"publisher","first-page":"6043","DOI":"10.1200\/JCO.2005.06.205","article-title":"Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti\u2013cytotoxic T-lymphocyte antigen-4","volume":"23","author":"Attia","year":"2005","journal-title":"J Clin Oncol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"2510","DOI":"10.1200\/jco.2006.24.18_suppl.2510","article-title":"Phase II trial of extended dose anti-CTLA-4 antibody ipilimumab (formerly MDX-010) with a multi-peptide vaccine for resected stages IIIC and IV melanoma","volume":"24","author":"Weber","year":"2006","journal-title":"J Clin Oncol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/nm.4321","article-title":"Is autoimmunity the Achilles\u2019 heel of cancer immunotherapy?","volume":"23","author":"June","year":"2017","journal-title":"Nat Med"},{"key":"B34","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"B35","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1172\/JCI91190","article-title":"IFN-gamma-related mRNA profile predicts clinical response to PD-1 blockade","volume":"127","author":"Ayers","year":"2017","journal-title":"J Clin Invest"},{"key":"B36","doi-asserted-by":"publisher","first-page":"e542","DOI":"10.1016\/S1470-2045(16)30406-5","article-title":"Predictive biomarkers for checkpoint inhibitor-based immunotherapy","volume":"17","author":"Gibney","year":"2016","journal-title":"Lancet Oncol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.cell.2016.02.065","article-title":"Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma","volume":"165","author":"Hugo","year":"2016","journal-title":"Cell"},{"key":"B38","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1158\/1535-7163.MCT-14-0983","article-title":"PD-L1 expression as a predictive biomarker in cancer immunotherapy","volume":"14","author":"Patel","year":"2015","journal-title":"Mol Cancer Ther"},{"key":"B39","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/nrc.2016.36","article-title":"Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy","volume":"16","author":"Topalian","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1097\/TP.0b013e3181d72091","article-title":"Chronic humoral rejection of human kidney allografts associates with broad autoantibody responses","volume":"89","author":"Porcheray","year":"2010","journal-title":"Transplantation"},{"key":"B41","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.autrev.2016.01.017","article-title":"Autoantibody production in cancer\u2014the humoral immune response toward autologous antigens in cancer patients","volume":"15","author":"Zaenker","year":"2016","journal-title":"Autoimmun Rev"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fimmu.2018.00411\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,3,2]],"date-time":"2018-03-02T04:21:06Z","timestamp":1519964466000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fimmu.2018.00411\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,2]]},"references-count":41,"alternative-id":["10.3389\/fimmu.2018.00411"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2018.00411","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,2]]},"article-number":"411"}}